This interview will appear in the January 2025 issue of Evidence-Based Oncology, our annual recap of the American Society of ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

Shares of Quantum Computing are on the rise as the artificial intelligence (AI) narrative continues to gain steam.

For the Nasdaq ticker, as of December 2024, that's around $11/share – unchanged from my last article. Here are my criteria and how the company fulfills them (italicized). This company is overall ...

The approval comes ahead of the cancer-focused biotech's plans to change its name to BeOne Medicines and switch its Nasdaq ticker symbol to “ONC” on January 2, 2025.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Tevimbra is already approved in the US for the treatment of unresectable or metastatic oesophageal squamous cell carcinoma (ESCC). SAN MATEO, Calif., December 27, 2024--BeiGene, Ltd. (NASDAQ: BGNE ...

U.S. stocks finished lower Tuesday, but closed out another remarkable year on Wall Street, as rising demand for artificial intelligence, a surprisingly resilient U.S. economy and the Federal Reserve's ...

Wall Street lost ground on Tuesday as investors closed the book on a remarkable year for equities, during which the U.S. stock market was powered to record highs by the twin engines of the ...

In our news wrap Thursday, Gaza health officials say Israeli airstrikes killed at least 40 people with one strike hitting a tent camp that Israel had designated as a safe zone, South Korean ...

Picked from S&P 500, refined by AI. This strategy studies all 500 stocks, then selects the elite 20 most likely to outperform the market in the next month.